Verrica Pharmaceuticals Shares Are Trading Lower After the Company Announced a Structuring to Reduce Costs and Expand Access to YCANTH for the Treatment of Molluscum Contagiosum. Also, Brookline Capital Downgraded the Stock From Buy to Hold.
Verrica Pharmaceuticals Shares Are Trading Lower After the Company Announced a Structuring to Reduce Costs and Expand Access to YCANTH for the Treatment of Molluscum Contagiosum. Also, Brookline Capital Downgraded the Stock From Buy to Hold.
verrica製藥股價下跌，公司宣佈重組以降低成本並擴大對YCANTH治療軟疣的獲取。此外，Brookline Capital將股票評級從買入調整爲持有。
Verrica Pharmaceuticals Shares Are Trading Lower After the Company Announced a Structuring to Reduce Costs and Expand Access to YCANTH for the Treatment of Molluscum Contagiosum. Also, Brookline Capital Downgraded the Stock From Buy to Hold.
verrica製藥股價下跌，公司宣佈重組以降低成本並擴大對YCANTH治療軟疣的獲取。此外，Brookline Capital將股票評級從買入調整爲持有。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。